Device Trial Radar · NCT07193953
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Nov 30, 2026
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Sunnybrook Health Sciences CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Focused Ultrasound Foundation
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS.
Conditions
- Amyotrophic Lateral Sclerosis
- ALS
Interventions
Next Generation Dome Helmet Focused UltrasoundDevice
Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.
Intravenous immunoglobulin (IVIG), 10% solution for infusionDrug
Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose. Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight.
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionDrug
DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of IVIg in patients with ALSTime frame: During and after IVIg administration at Week 0 and Week 2 Day 1 until Week 24.
- Safety of DEFINITY® microbubblesTime frame: During and after DEFINITY® administration at Week 2 Day 1 until Week 24.
- Feasibility of FUS BBB opening in the motor cortexTime frame: During and after Week 2 Day 1 FUS BBB opening until Week 24.
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.